Shares of Advaxis Inc. plunged 36.6 percent Wednesday after the North Brunswick, N.J.-based company revealed that the FDA had denied its orphan drug designation application for ADXS11-01 (formerly Lovaxin-C) as an immunotherapy for invasive cervical cancer. (BioWorld Today) Read More
